Human Cell Lines with Mannosyl Oligosaccharide Glucosidase (MOGS) Defect for the Study and Prevention of Infection

Description:
This technology includes human cell lines from patients who have genetic defects in MOGS, the gene encoding mannosyl-oligosaccharide glucosidase, causing the rare congenital disorder of glycosylation type IIb, also known as MOGS-CDG. This defects appears to impair the ability of viruses to infect a second round of cells, which can be used to study and prevent infections. This is likely related to impaired viral replication and cellular entry. This finding has implications for Ebola and Zika, as well as other viral infections.
Patent Information:
For Information, Contact:
Eggerton Campbell
Licensing And Patenting Manager
NIH Technology Transfer
301-402-1648
eggerton.campbell@nih.gov
Inventors:
Cynthia Tifft
Sergio Rosenzweig
David Adams
Lynne Wolfe
William Gahl
Keywords:
Cell
Defect
GLYCOPROTEIN
Glycosidase
Human
Lines
Mannosyl
MOG
MOGS
MYELIN
Oligodendrocyte
Olygosaccharide
VLXXXX
VPXXXX
WIXXXX
© 2024. All Rights Reserved. Powered by Inteum